Our Team Fundraising Page

Join our team or make a donation today!

Why We Walk

DiaMedica Therapeutics is developing DM199 (rhKLK1), a recombinant protein replacement therapy intended to restore normal, healthy levels of human tissue kallikrein-1 (KLK1). KLK1 is a naturally occurring protein believed to stimulate the production of key vasodilating signaling molecules that help to increase blood flow and improve endothelial health. Through this novel mechanism, DM199 may have the potential to treat several ischemic conditions, including preeclampsia, fetal growth restriction, and and other vascular diseases.

$3,717.50

achieved

$4,000.00

goal

of your goal reached

Join My Team

Recent Activity

Our Supporters

  • JANE CONLON-WERNER Last month
  • Nick Paulson September 2026 $210.00
  • Teri Wilson September 2026 $100.00
  • Scott Kellen September 2026 $200.00
  • Scott Kellen September 2026 $100.00
  • DiaMedica Corporate donation February 2026 $2,500.00
  • Nick Paulson September 2026 $210.00
  • Scott Kellen September 2026 $200.00
  • Kelly Hagglund July 2026 $200.00
  • Aaron Olson August 2026 $105.00